Alliance for Regenerative Medicine Releases Annual Industry Report Showcasing Impressive Sector Growth - Seite 2
Highlights from the report include:
- An overview of the RM and advanced therapy landscape, including a clinical development breakdown by therapeutic area for 45 primary cell-based therapeutic companies, 91 stem cell and progenitor
cell-based therapeutic companies, 42 cell-based immunotherapy companies and 69 gene therapy companies - 67% of the products these companies are developing are in mid to late-stage clinical
trials
- Milestones anticipated for 2014 including investigational new drug filings (INDs) and more than 20 clinical data readouts for heart disease, stroke, ALS, ulcerative colitis, kidney failure,
various cancers and macular degeneration to name a few
- A twelve-month financial overview of investment activity and market performance for the field including top deals, financings and acquisitions - financings for the year totaled $2.3 billion,
significantly up from prior years
- Results from the ARM Pharmaceutical and Large-Cap Biotech Survey highlighting industry perspectives on RM investing, specific areas of interest, business strategies for pursuing RM, near- and
long-term therapeutic opportunities and potential challenges - 100% of the 16 companies interviewed are already investing in RM in some capacity
"The Regenerative Medicine Annual Industry Report is an invaluable resource providing a clear snapshot of the regenerative medicine industry today and the groundbreaking advancements on the horizon," said Morrie Ruffin, Managing Director of ARM. "We are increasingly excited about the future of regenerative medicine and the continued collaboration of all constituents as the field makes exciting progress in bringing new therapies to those who need them."
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder advocacy organization that promotes
legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field
and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the
formation of ARM in 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of the companies, research institutions, investors and patient
groups that comprise the entire regenerative medicine community. Today ARM has more than 150 members and is the leading global advocacy organization in this field. To learn more about ARM or to
become a member, visit www.alliancerm.org.
Lesen Sie auch
CONTACT:
Media Contact:
Michelle Linn
Linnden Communications
Phone: 774-696-3803